Skip Ribbon Commands
Skip to main content
Dr Vanessa Au

Dr Vanessa Au

Mbbs, Mrcp (UK), MMed (Int Med)

Senior Consultant

Changi General Hospital

Specialty: Endocrinology

Clinical Appointments

  • Senior Consultant Endocrinology Changi General HospitalChangi General Hospital


Dr Au is a Senior Consultant with the Department of Endocrinology at Changi General Hospital. Dr Au graduated from the National University of Singapore. After completing specialist training in endocrinology, she was awarded a Health Manpower Development Program fellowship in Sydney, Australia. Her interests are general endocrinology and internal medicine.


Professional Appointments and Committee Memberships

  • Associate Program Director, Endocrinology Senior Residency Program
  • Clinical Senior Lecturer, NUS Yong Loo Lin School of Medicine
  • EMSS secretary 2016
  • Medical Audit Committee member 2012
  • Pharmacy and Theurapeutic Committee Deputy Chair 2008


Research Interests


2000 V Au, Lee CH Hyperlipidaemia Management strategy. The Singapore Family Physician 2000;26(2):43 Singapore

2002 Chen YT, Mukherjee JJ, Lee CH, Au VSC, Tavintharan S. Comparing fasting plasma glucose against two-hour post-load glucose concentrations for the diagnosis of diabetes mellitus and glucose intolerance in Singaporean hospital patients. Ann Acad Med Singapore 2002; 31(2):189-94

2005 Chuah KL, Hwang JS, Ng SB, Tan PH, Poh WT, Au VS Cytologic features of cribriform-morular variant of papillary carcinoma of the thyroid: a case report. Acta Cytol.2005 Jan-Feb;49(1):75-80.

2011 Tay TL, Foo JP, Tan E, Chen R, Khoo J, Soh SB, Au V, Cho LW. HbA1c may not be a sensitive determinant of diabetic status in the elderly. Diabetes Res Clin Pract. 2011;92:e31-3

2012 Khoo J, Tay TL, Foo JP, Tan E, Soh SB, Chen R, Au V, Jen-Min Ng B, Cho LW. Sensitivity of A1C to diagnose diabetes is decreased in high-risk older Southeast Asians. J Diabetes Complications 2012; 26:99-101

Research Trials

2002 - 2010 Co InvestigatorStudy Title: A multinational, randomised, double-blind, placebo-controlled, force-titration, 2 x 2 factorial design study of the efficacy and safety of long term administration of nateglinide and valsartan in the prevention of diabetes and cardiovascular outcomes in subjects with Impaired Glucose Tolerance (IGT)

2007-2008 Co Investigator An open-label phase i/ii study to assess the safety and immunogenicity of two doses of a vero cell-derived, whole virus clade 2 h5n1 influenza vaccine in healthy volunteers aged 21 to 45 years

2007-2008 Co Investigator A phase III, observer-blind, randomized controlled study in adults aged between 18 and 60 years to assess the lot-to-lot consistency of the immunogenicity of a GlaxoSmithKline Biologicals’ pandemic influenza vaccine (split virus formulation adjuvanted with AS03)

2008 Co Investigator Pharmacokinetics Study of NKP-5191TF

2008 -2011 Co Investigator Phase III, open, multicentre, randomized study in adults to assess the immunogenicity of a pandemic monovalent influenza vaccine (GSK 1562902A), administered at different boosting vaccination schedules.

2009 Co Investigator Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 in Singapore – Multicenter, observer-blind for the first and second vaccinations and single-blind for the third, one, randomized, controlled, Phase II trial in 1,200 subjects. Three vaccinations over a period of 1 year, with a 4-year follow up after the last vaccination.

2010 Co Investigator Study on the Effect of Granulated GlucosCare® Herbal Tea in Type 2 Diabetes Mellitus patients (Non-insulin requiring)

2011-ongoing Co Investigator A double-blind, randomized, placebo-controlled, age descending and expansion Phase II study to investigate the immunogenicity and safety of a tetravalent chimeric dengue vaccine in healthy volunteers between the ages of 18 months – 45 years old.

2014 Co Investigator A 24-week Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy & Safety of Dapagliflozin Added to the Therapy of Asian Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Insulin